期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 14, 期 2, 页码 619-631出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2017.12.004
关键词
Early targeting therapy; Nanovector; Dendrigraft poly-L-lysine; miRNA-1; Myocardial infarction
资金
- National Natural Science Foundation of China [81470390, 81671944, 51473124]
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152218]
- Clinical Research Plan of SHDC [16CR3006A]
- Shanghai Science and Technology Commission Fund [17411954700]
Myocardial infarction (MI), known to be rapidly progressed and fatal, necessitates a timely and effective intervention particularly within golden 24 h. The crux is to develop a therapeutic agent that can early target the infarct site with integrated therapeutic capacity. Finding the AT(1) receptor being most over-expressed at 24 h after MI, we developed a nanovector (AT(1)-PEG-DGL) anchored with AT(1) targeting peptide, and simultaneously armed it with specific microRNA-1 inhibitor (AMO-1) to attenuate cardiomyocyte apoptosis. In vivo imaging after IV administration demonstrated that AT(1)-PEG-DGL quickly accumulated in the MI heart during the desired early period, significantly outperforming the control group without AT(1) targeting. Most importantly, a pronounced in-vivo anti-apoptosis effect was observed upon a single IV injection. Apoptotic cell death in the infarct border zone was significantly decreased and the myocardial infarct size was reduced by 64.1% as compared with that in MI control group, promising for early MI treatment. (c) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据